Atova's September Regulatory Roundup!


✨ Welcome to the September 2026 edition of the Atova Regulatory Roundup! As we head into the final quarter of the year, it’s been a busy month for the Atova team, with plenty happening across the global regulatory and food innovation landscape. In this edition, we’re sharing the latest from Atova, including news of our upcoming Navigating Novel Foods webinar, a new publication exploring EFSA’s approach to genotoxicity, and highlights from our team’s recent and upcoming events across Europe and Asia. Alongside our own updates, we’ve rounded up key regulatory developments from around the world to help you stay informed on the latest developments shaping novel foods, alternative proteins and food technology. 🌱

From our final Navigating Novel Foods: EU Dossier Masterclass session to a new publication exploring EFSA’s approach to genotoxicity and events across Europe and Asia, we’re looking forward to sharing our expertise, catching up with colleagues, clients and innovators along the way.
Registration is now open for the final part of our Navigating Novel Foods: EU Dossier Masterclass series!
Registration is open for Part 4 of our Navigating Novel Foods EU Dossier Masterclass series.
Join Dr. Fernando Rivero Pino, Regulatory Scientist & Toxicologist at Atova, on Thursday 26th November 2026 at 15:00 CET for a practical session covering ADME, toxicology, allergenicity and EFSA expectations. Fernando will share key considerations for preparing these important sections of your novel food dossier, including common challenges, potential pitfalls and what to consider when responding to questions or requests for additional data during EFSA’s assessment.
Whether you’re preparing a new application or looking to strengthen an existing dossier, this session will provide valuable insights to help you prepare your safety data clearly and confidently for EFSA review.
New publication on EFSA’s approach to genotoxicity in novel food applications
We’re very excited to share a newly published article from Atova's Fernando Rivero Pino and Hannah Lester, exploring how genotoxicity has been assessed across the European Food Safety Authority (EFSA) novel food evaluations. Their review looks at regulatory precedents, testing strategies and the scientific reasoning behind individual cases, providing a valuable overview of how EFSA assesses genotoxicity studies.
Some key insights include:
🔬 In vitro genotoxicity testing has generally provided the basis for addressing genotoxicity concerns, providing a strong foundation for safety assessment.
🧪 In vivo testing has been needed in some cases to resolve positive, equivocal or otherwise unresolved in vitro findings, with the choice of study guided by the endpoint and evidence of exposure.
📋 EFSA’s approach has evolved, with updated guidance contributing to greater consistency in study design and interpretation.
💡 Regulatory precedents can provide valuable insight for applicants when developing and justifying genotoxicity testing strategies for future novel food applications, while EFSA guidance remains the primary reference.
The review also explores the challenges of assessing diverse novel food matrices, including the importance of considering composition, manufacturing processes and the relevance and suitability of the test material. As food innovation continues to advance, robust safety assessment remains the foundation of bringing novel foods to the EU market. This is a particularly valuable resource for those working in novel foods, regulatory safety assessment and toxicology. It’s always exciting to see the team contributing to the wider scientific and regulatory discussion around novel food safety and we´re excited to see this publication out in the world!
Read the full article here.

Where team Atova are heading next
It’s been a busy September for the Atova team, with a packed calendar of events and plenty of opportunities to connect with colleagues, clients and friends across the food and regulatory landscape.
Hannah and Steph kicked off our busy conference season at Future Food-Tech in London, where they enjoyed catching up with many of you and hearing about the latest developments, innovations and challenges shaping the future of food.
Hannah then headed back to Barcelona for Navigating the Feed and Food Regulatory Landscape, joining discussions around evolving policy landscapes, market access and the regulatory trends shaping the industry.
To round off the month, Hannah and Hannes joined an expert panel at LIKE-A-PRO in San Sebastián, discussing regulatory and safety pathways for alternative proteins and how regulatory frameworks can help support and accelerate the transition towards scalable and widely accepted alternative protein products.
And that’s not the end of our travels for 2026! So, where is the Atova team heading next?
Foodtech Co-Creation Seminar | Japan | 8 October
Hannah will be heading to Japan to speak at the Foodtech Co-Creation Seminar with Hokkaido’s Food Industry in Sapporo. The seminar will explore the current landscape for cultivated foods and precision fermentation, as well as opportunities for collaboration with Hokkaido’s food industry, including approaches to intellectual property and protecting producers’ rights. Organised by the Hokkaido Bureau of Economy, Trade and Industry (METI) and the Japan Association for Cellular Agriculture (JACA), the event will bring together experts from across the foodtech and regulatory landscape. Hannah will join Dr Joshua Ravenhill (FSA), Kimberly Ong (Vireo Advisors), and David Ettinger (Keller and Heckman) for a panel discussion on ‘Overview of Policy and Technology Trends in the Foodtech Sector Overseas’.
Japan Cell-Ag-Ready | Japan | 9 October
From Sapporo, Hannah will make her way to Tokyo to speak at the Japan Cell-Ag Ready Dialogue. The event will bring together regulatory scientists and experts from Korea, China, Europe, the US and Japan to share the latest developments in the safety assessment and industrial development of cultivated foods, as well as discuss how these emerging technologies can be effectively communicated.
Hannah will join Dr Satoshi Kitajima, Kimberly Ong, and Ryan Simon for a panel discussion on ‘Latest Discussions on Food Safety’, exploring some of the key regulatory and safety considerations shaping the cultivated food sector.
Singapore International Agri-Food Week (SIAW) | Singapore | 26–29 October
Later in October, Hannah will be attending Singapore International Agri-Food Week (SIAW), one of the region's leading agri-food events. Bringing together policymakers, researchers, investors, entrepreneurs, food producers and industry leaders, the conference provides a platform to explore emerging technologies, strengthen food security and climate resilience, and shape the future of food production across Asia and beyond. As part of SIAW, Hannah will be attending the Asia-Pacific Agri-Food conference, which will focus on discussions examining how AI‑first R&D and biomanufacturing are reshaping agtech and foodtech innovation ecosystems.
The Future of Protein Production | Amsterdam | 4–5 November
Rounding off a busy few months, Hannah Lester will be taking to the stage at the Future of Protein Production conference x Cultured Meat Symposium in Amsterdam. Hannah will be speaking on day two of the conference alongside Marnie Hewat, Valeria Teloni, Nicolas Morin-Forest and Stoffer Loman where they will share their experiences navigating the European approval pathway. The discussion will explore what it really takes to prepare for an EU novel food application, from safety data and scientific validation to EFSA expectations, regulatory strategy, and the practical realities of submission.
If you'll be attending any of these events, we'd be delighted to connect and discuss the latest industry developments and regulatory strategy.

EFSA Updates
Novel Food Dossier and Traditional Food Notifications Received
The European Food Safety Authority (EFSA) received two novel food applications in September:
Name of Product | Dossier Received by EFSA |
14/09/2026 | |
08/09/2026 |
Validated Dossiers
Four novel food dossiers were validated dossiers and published on Open EFSA in September.
Name of Product | Dossier Received by EFSA | Validated | Time until validation |
23/04/2026 | 28/09/2026 | ca. 5 months | |
31/07/2025 | 22/09/2026 | ca. 13.5 months | |
20/07/2026 | 22/09/2026 | ca. 2 months | |
08/05/2026 | 14/09/2026 | ca. 4.5 months |
Dossiers Considered Non-Valid and Withdrawn Dossiers
Ten dossiers were considered non-valid or withdrawn in September. Out of these ten dossiers, nine were declared as non-valid and one was withdrawn by the applicant.
Name of Product | Dossier Received by EFSA | Declared Non-Valid / Withdrawn | Time until Non-Valid / withdrawn |
08/04/2022 | 27/09/2026 | ca. 54.5 months | |
07/04/2022 | 27/09/2026 | ca. 54.5 months | |
07/04/2022 | 27/09/2026 | ca. 54.5 months | |
23/05/2022 | 25/09/2026 | ca. 52.5 months | |
29/11/2021 | 24/09/2026 | ca. 58.5 months | |
07/04/2022 | 24/09/2026 | ca. 54.5 months | |
27/07/2021 | 24/09/2026 | ca. 62.5 months | |
31/08/2021 | 17/09/2026 | ca. 61.5 months | |
18/02/2022 | 17/09/2026 | ca. 55.5 months | |
22/02/2024 | 17/09/2026 | ca. 31.5 months |
EFSA Public Consultations
Five EFSA novel food opinions were published on Open EFSA during September.
Safety of Acheta domesticus (house cricket) spray-dried powder as a Novel food pursuant to Regulation (EU) 2015/2283
Received on 30/05/2023, validated on 13/08/2024 and opinion published on 25/09/2026 (40.5 months) – EFSA could not conclude of safety citing unresolved microbiological and chemical contamination concerns and inadequate specifications.
Received on 18/06/2021, validated on 15/02/2022 and opinion published on 21/09/2026 (64 months) - EFSA could not conclude of safety because data gaps remained and the applicant did not respond to requests for additional information.
Safety of Cannabis sativa L. extract as a novel food pursuant to Regulation (EU) 2015/2283
Received on 11/08/2021, validated on 15/02/2024 and opinion published on 21/09/2026 (62.5 months) - EFSA could not conclude of safety because data gaps remained and the applicant did not respond to requests for additional information.
·Safety of synthetic cannabidiol as a novel food pursuant to regulation (EU) 2015/2283
Received on 20/03/2020, validated on 07/07/2020 and opinion published on 18/09/2026 (79 months) – EFSA concluded that the novel food is safe under the proposed conditions of use, except for people taking medication, for whom safety could not be established.
Safety of S-acetyl glutathione as a novel food pursuant to Regulation (EU) 2015/2283
Received on 18/10/2024, validated on 27/05/2025 and opinion published on 01/09/2026 (22.5 months) – EFSA concluded that the novel food is safe when consumed at intake levels up to 190 and 269 mg/day, respectively, assuming similar tolerance on a body weight basis as compared to adults.
Atova Insights
Spray-dried Acheta domesticus (house cricket) – what is behind the negative opinion?
EFSA could not establish the safety of spray-dried house cricket powder even though other novel food assessments for the same species have been positive.
What was submitted? Production details, batch composition, contaminant and microbiological analyses, stability data, and nutritional and particle-size evidence. EFSA requested clarification on food-contact material compliance, chitin methods and microbial variability, additional lipid-oxidation data, and a tiered small-particle assessment.
Toxicology and small particles: Published genotoxicity and 14- and 90-day toxicity studies used a different cricket powder, so provided supporting evidence only; the submitted cytotoxicity study was considered irrelevant. Potentially insoluble particles below 250 nm remained insufficiently characterised. EFSA stressed that toxicological testing would need appropriate particle dispersion to be valid under its guidance.
Why no safety conclusion? Variable and elevated microbial counts, mineral oil aromatic hydrocarbon (MOAH) contamination, phthalates with incomplete food-contact documentation, and inadequate specifications left fundamental concerns unresolved. EFSA did not request further particle or toxicology studies because these would not resolve those problems.
The first CBD dossier to get a positive EFSA opinion!
What set this dossier apart from so many others that have failed? EFSA concluded that Chanelle McCoy CBD Ltd.’s synthetic cannabidiol is safe at 2 mg/day, dissolved in medium-chain triglyceride (MCT) oil, for adults aged 25 or above, excluding pregnant and breastfeeding women. Safety for people taking medication remains unestablished.
What was submitted? Six-batches for characterisation, impurity and stability data, and product-specific toxicology supported the assessment. A 90-day rat study identified liver effects, with females being more sensitive.
EFSA’s additional data requests: Requests covered microbiology, oxidative degradation products, tighter specifications and repeat testing to resolve equivocal genotoxicity findings. Small-particle concerns were addressed by demonstrating that CBD remains dissolved in MCT oil without reprecipitating.
Why did this application succeed? The applicant reduced its proposed intake from 25 to 2 mg/day, aligning with EFSA’s updated framework. Requested reproductive/developmental and human studies were not supplied; EFSA accepted restricted uses and population alongside a 400-fold uncertainty factor addressing remaining gaps. Production, composition and specifications were acceptable, and genotoxicity concerns were resolved.
EFSA Public Consultations
Four novel food public consultations on novel food applications were closed in September; the dates in brackets are consultation deadlines:
Application for authorisation of Coffee fruit extract as a novel food (28/09/2026)
Application for authorisation of Human-equivalent lactoferrin alpha (heqLFα) as a novel food (17/09/2026)
Application for authorisation of Gamma -Aminobutyric acid as a novel food (15/09/2026)
Application for a modification of the authorised 6'-Sialyllactose (6'-SL) sodium salt as a novel food (11/09/2026)
A further consultation concerns a draft mandate for preparatory work towards guidance on combined chemical exposure, with a deadline in October:
EFSA Working Group and NDA Panel Plenary Meetings
The 171st Plenary meeting of EFSA´s Scientific Panel on Nutrition, Novel Foods and Food Allergens is available online. This meeting was held on the 29-31st September, where the draft opinions for Appethyl®, Jatropha curcas L. (Xuta) Kernels, Mangosteen peel extract and Spermidine trihydrochloride were all submitted for discussion and possible adoption. The agenda is available here.
The 23rd Plenary Meeting of EFSA’s Panel on Food Enzymes (FEZ) is due to take place on 6–8th October 2026. The draft agenda is available to view here.
EFSA paper on needs for scientific excellence and regulatory readiness
A new EFSA paper highlights the need for regulatory science to keep pace with rapid innovation and increasingly complex food systems. Key priorities include fit-for-purpose approaches for novel foods and technologies, greater use of New Approach Methodologies (NAMs), omics and exposure science, and stronger One Health collaboration around areas such as antimicrobial resistance, sustainability and climate-related risks.
The paper also highlights the growing role of AI and data in strengthening foresight, predictive modelling, preparedness and risk communication. Ultimately, EFSA emphasises the importance of a human-led, AI-enabled approach, supported by continued investment in scientific expertise, data, research and collaboration to deliver faster, consistent and future-ready food safety advice while maintaining transparency and public trust. Read more here.
EFSA call for general pre-submission advice (GPSA)
EFSA has launched a new call for SMEs working in novel foods that are interested in receiving tailored advice on the requirements for EU novel food authorisation through a dedicated tele-meeting. The initiative is particularly aimed at SMEs with limited experience in preparing applications, with advice available at both the early development stage and during the final stages of dossier preparation.
The initiative aims to make EFSA’s General Pre-Submission Advice service more accessible to SMEs, helping applicants better understand requirements before submitting their application. Information shared through the process will be treated confidentially, and expressions of interest must be submitted by 18 November 2026 at 13:00 CET. Find out more here.
EFSA announce Safe Food, One Future Conference
EFSA will mark its 25th anniversary with the Safe Food, One Future Conference, taking place in Parma, Italy and online from 29 September to 1 October 2027. The event will bring together scientific experts, policymakers and food safety stakeholders to reflect on 25 years of scientific collaboration and look ahead to the future of European food safety.
The conference will also launch EFSA’s Strategy 2034, with discussions focused on sustainable innovation, advances in regulatory science, One Health and sustainability, emerging risks and preparedness, risk communication and social science, and the use of data, digitalisation and AI. Registration is expected to open in January 2027, with the programme launching in December 2026. Find out more here.
European Commission Updates
Standing Committee on Plants, Animals, Food and Feed (SCoPAFF) Meetings
The Novel Food and Toxicological Safety meeting took place on 25th September. The agenda for this meeting is available here. The next meeting on General Food Law is provisionally due to take place on 16th October.
Article 4 Novel Food Consultations
Three Article 4 consultation outcomes were published in September, including one outcome covering four mushroom extracts. These determinations concern the specific products, production processes and uses assessed.
The outcome of an Article 4 novel food consultation concerning lipids produced by the yeast Cutaneotrichosporon oleaginosum has been published by the Czech Republic Ministry of Agriculture, Food Safety Department. The consultation concerns lipids from yeast, with the final product consisting mainly of triglycerides (approx. 93.6%), a minor amount of mono- and diglycerides, with around 99.5% total fat.The lipids are intended for use as an ingredient in a range of food products, including plant-based dairy alternatives, chocolate fillings, spreads, bakery release agents, bouillon cubes and blended margarine. The production process starts with pasteurisation of concentrated whey permeate which is mixed with a sterilised fermentation medium. The yeast (Cutaneotrichosporon oleaginosum) is then added and grown under controlled conditions. It undergoes fermentation, pasteurisation, and mechanical extraction of the lipids from the dried yeast biomass. It is also noted that no solvents were used and the yeast is completely removed from the final product.
Conclusion:
❌ Novel Food – Lipids from Cutaneotrichosporon oleaginosumThe consultation was considered a novel food due to insufficient evidence of significant consumption of lipids produced by yeast in the EU before 15 May 1997. Importantly, the conclusion was not based on the fatty acids themselves being unfamiliar. The fatty acids present are also found in fats and oils from plant and animal sources with a history of consumption, but rather the fact they were produced from yeast (Cutaneotrichosporon oleaginosum) which represents a new source not used before May 1997.
The outcome of an Article 4 novel food consultation concerning aqueous powder extracts from four mushroom species has been published. The consultation, submitted to the Czech Republic Ministry of Agriculture, Food Safety Department, concerns a powdered extract obtained from the fruiting bodies of:- Ganoderma lucidum (Reishi)- Lentinula edodes (Shiitake)- Hericium erinaceus (Lion’s Mane)- Inonotus obliquus (Chaga)The extracts are produced using a process involving mechanical grinding, water extraction, multi-stage membrane filtration, tangential flow filtration and freeze-drying. The intended uses considered in the consultation include food products and food supplements for Ganoderma lucidum, Lentinula edodes, Hericium erinaceus, while Inonotus obliquus is intended for use in food supplements as a powder, tablet, capsule or softgel.
Conclusion:
✅ Not Novel – aqueous fruiting-body extract of Ganoderma lucidum (Reishi)✅ Not Novel – aqueous fruiting-body extract of Lentinula edodes (Shiitake)✅ Not Novel – aqueous fruiting-body extract of Hericium erinaceus (Lion’s Mane)✅ Not Novel in food supplements – aqueous fruiting-body extract of Inonotus obliquus (Chaga)
The consultation concludes that the fruiting bodies of the mushrooms Ganoderma lucidum, Lentinula edodes, and Hericium erinaceus all have a significant history of consumption in the EU before 15 May 1997. In the case of Inonotus obliquus there is a history of use for human consumption to a significant degree in food supplements before May 1997. It was also noted that there were no significant changes in composition or structure which would affect nutritional value, metabolism, or levels of undesirable substances.
An Article 4 novel food consultation outcome has recently been published, this time concerning asafoetida (Ferula assa-foetida L.).The consultation, published by the Czech Republic Ministry of Agriculture, Food Safety Department, concerns natural oleo-gum-resin obtained from the root of the asafoetida plant. This is intended for use as a spice and seasoning in foods, including ready-made Indian sauces and other composite savoury foods. In the product assessed, asafoetida is present at a concentration of 0.1%. The oleo-gum-resin is obtained by making incisions in the plant's root and collecting the exudate. This is then cleaned, sorted, dried and milled, with food-grade carriers potentially added before packaging. The application does not cover essential oils, purified extracts, flavouring preparations or other modified preparation.
Conclusion:
✅ Not Novel – Asafoetida (Ferula assa-foetida L.)The available evidence was considered sufficient to demonstrate a history of significant consumption as a food ingredient in the EU before 15 May 1997. The information also demonstrated the product has undergone a traditional production process and is not novel for its intended use as a spice and seasoning.
EU: precision-fermentation clarification advances in the food and feed omnibus
The Council adopted its negotiating position on Omnibus X, supporting clarification that fermentation products made using genetically modified microorganisms are not food or feed “produced from GMOs”. Its position also envisages Commission guidance on manufacturing practices to minimise residual GMM material. Potentially significant for fermentation-derived ingredients, but this remains a legislative proposal requiring agreement with Parliament. Find out more here.

FSA Board Meeting
The FSA Board held a meeting on 16th September 2026. The agenda for this meeting included discussions on the FSA sanitary and phytosanitary programme, CBD novel food applications, future of food regulation report, meat charging discount, FSA science update, and committee reports. You can view the agenda here.
New guidance for cell-cultivated food
The Food Standards Agency (FSA) and Food Standards Scotland (FSS) have published new guidance today for businesses developing cell-cultivated products (CCPs) in Great Britain. Published through the CCP Sandbox Programme, the latest guidance provides further detail on two important areas:
Regulatory authorisation – explaining how the regulated products framework applies to cell-cultivated products, including how changes to an authorised product should be managed.
Growth media and toxicology – providing scientific considerations for assessing growth media components and potential toxicological hazards as part of a CCP safety assessment.
This is the third batch of guidance documents to be published through the Sandbox Programme, which runs until February 2027. For businesses developing CCPs for market authorisation, these developments are useful additions to the growing body of information available on the Great Britain regulatory pathway. The FSA has also recently published research on analytical methods for cell-cultivated products and the potential impact of genetic drift on product safety. These publications provide further areas for businesses to consider when developing their safety evidence and planning their regulatory strategy.
Read all their guidance here.
Atova will be following the continued development of the framework closely as the Sandbox Programme progresses towards its conclusion in February 2027.
Consultation opens on 16 novel food applications
The public consultations include fermentation-produced human milk oligosaccharides and changes to existing authorisations, including proposed uses in supplements for infants. The FSA deadline is 16 November; Scotland’s parallel consultation closes 24 November. Read more here.
178th ACNFP meeting – 16th and 17th September 2026
The advisory committee on novel foods and processes (ACNFP) September agenda highlights progress across fermentation-derived proteins and cultivated foods, alongside a broader review of how novel-protein safety should be assessed. The main items discussed were:
EniferBio’s fungal biomass — RP2305: First review of Paecilomyces variotii KCL-24 biomass, produced by continuous fermentation for use as a protein-rich food ingredient. Members were asked whether the evidence supported safety or further data were needed.
Perfect Day’s beta-lactoglobulin — RP1571: Review of responses addressing outstanding composition and specification questions, to determine whether the assessment could conclude positively.
Cultivated duck — RP2241: Consideration of additional applicant information to progress the assessment.
Mosa Meat’s cultivated bovine fat — RP2307: First full application review, identifying assessment priorities and data gaps.
CBD Group C — RP450: Second review to complete the initial assessment and identify outstanding questions. These three items were reserved business.
Novel-protein safety workshop: Exploration of appropriate safety margins, limitations of high-dose animal studies and supporting evidence for setting safe consumption levels
Workshop on assessing the safety of biomass-derived dietary proteins
The ACNFP is exploring whether conventional toxicology approaches are always appropriate for biomass-derived dietary proteins, including microbial and fungal proteins consumed at substantial dietary levels.
The September discussion paper raises three central issues:
Is a margin of safety of 100 always necessary? The Committee was asked when a lower margin could be scientifically justified by strong product characterisation, human evidence, history of safe use, mechanistic understanding and consistent findings across studies.
What does the highest tested dose actually tell us? Animal studies may reach a maximum feasible dose because higher inclusion causes nutritional imbalance, poor palatability or physical bulk effects. A study showing no adverse effects at that dose may therefore provide limited information about a biological toxicity threshold.
How should supporting evidence address uncertainty? The workshop will consider digestibility, ADME, nutritional studies, human data, read-across and other evidence, alongside criteria for requesting further toxicological studies.
This opens up an important discussion around proportionate, integrated assessments where conventional studies constrain the derivation of safe consumption levels.
The minutes have not yet been published, but we will update you in October´s regulatory roundup. Find out more about the workshop here.

The U.S. Food and Drug Administration (FDA) has published its annual Pesticide Residue Monitoring Program Report for Fiscal Year 2024, covering testing carried out between October 2023 and September 2024.
The programme monitors pesticide residues and selected industrial compounds in human and animal foods to assess compliance with maximum residue levels (tolerances) established by the U.S. Environmental Protection Agency (EPA). Testing focuses particularly on raw agricultural commodities that contribute significantly to dietary exposure, as well as foods commonly consumed by infants and young children.
Overall, the FY 2024 findings indicate that pesticide residue levels in the U.S. food supply were generally within applicable EPA tolerances. Read more here.
Owners, operators, or agents in charge of a domestic or foreign facility subject to FDA food facility registration requirements that manufactures, processes, packs, or holds food for consumption by humans or animals in the United States must renew their FDA registration every two years, during the renewal period from 1 October to 31 December. Facilities that qualify as “qualified facilities” must also submit an attestation confirming their status within this period. Find out more here.
The FDA has published the 2026 edition of the FDA Food Code, a model framework designed to support food safety and public health across US retail and food service settings. Updated every two years, the Food Code reflects developments in food safety science, regulatory practice and emerging industry trends.
The 2026 edition introduces several updates, including requirements for written employee illness policies, an alternative cooling process for certain foods, and provisions for double gloving in specific circumstances. It also provides updates covering areas such as allergen cross-contact, food donations, specialty mushroom safety, dehydration and freeze-drying, mobile food establishments, and vending machine controls. Read more here.

Canada
Health Canada updated the assessment page of the assessment for Saccharomyces cerevisiae (brewer's yeast) strain BY-989 to make the assessments information publicly available. Read this assessment here.
Food Standards Australia New Zealand
Food Standards Australia New Zealand (FSANZ) has updated the Nutrition Panel Calculator (NPC) dataset with revised food and nutrient information to support accurate Nutrition Information Panel calculations. New recipes will automatically use the updated dataset, while existing recipes will retain the data available when they were created. To apply the updated data to an existing recipe, users should recreate it. Some previously available ingredients may also have been removed and can be replaced with a similar ingredient or added manually using the custom ingredient tool.
FSANZ’s September notification circular reports acceptance of application A1364 for Rhiza mycelium (Neurospora crassa) biomass as a novel food, following administrative assessment. The application was accepted on 24 August 2026; acceptance is not approval for sale. A public consultation will be announced at a later stage.[1]
FSANZ’s September communiqué records in-principle support for the proposed approach to application A1341, covering cultivated duck biomass for products such as foie gras and pâté. An extraordinary Board meeting is scheduled for 6 October, with food ministers requesting subsequent consideration in-session. Read more here.
India
The Food Safety and Standards Authority of India (FSSAI) has introduced updated regulations governing food laboratory testing and sample analysis, replacing the previous 2011 framework. The new requirements introduce defined timelines for issuing analysis reports, including a maximum of 14 days for regulatory samples and appeals and 5 days for import samples. The regulations also allow validated analytical methods from recognised organisations, including AOAC, ISO and Codex Alimentarius, to be used where a relevant method is not specified in FSSAI’s official manuals. In addition, the updated framework streamlines certificate submissions and removes the use of Forms A and B. The FSSAI document is available here.
FAO
The Joint FAO/WHO Expert Committee on Food Additives (JECFA) has published a practical toolbox outlining its approach to assessing the risks associated with veterinary drug residues in food derived from animals. The resource explains the six key sections of the risk assessment process, introducing relevant scientific principles, outlining the steps followed by JECFA and providing practical examples. It also highlights the importance of data quality in risk assessments and signposts additional guidance for more detailed information. The toolbox aims to support a better understanding of how veterinary drug residues are evaluated to protect consumer health while facilitating international trade in animal-derived food products.
A new article in the Journal of Food Protection explores how robust scientific evidence and clear communication support food safety decision-making. The authors highlight challenges including emerging technologies, data quality, scientific uncertainty and misinformation, and emphasise the importance of transparent research and effective communication between scientists, regulators, industry and consumers.
FAO took part in the 16th Global Microbial Identifier (GMI) Conference in Tunis, highlighting the role of whole genome sequencing, AI and data sharing in food safety. Discussions emphasised the importance of high-quality data, international collaboration and responsible use of emerging technologies to strengthen food safety monitoring and research.
Canada published two useful non-novel determinations on 5 August:
Sidr (Ziziphus spina-christi) pulp powder; and
VITACEL Citrus Fiber, an insoluble fibre derived from citrus peel.
Both were considered non-novel based on history of safe food use. Find the full list here.
Food Standards Australia New Zealand
New guidance published on GM food and novel DNA definitions
Food businesses and regulators in Australia and New Zealand can now access new guidance on the updated definitions of genetically modified food and novel DNA in the Food Standards Code. The guidance provides practical information and examples to help clarify how the new definitions should be interpreted and applied, following their adoption in September 2025 under Proposal P1055. Read the guidance.
FSANZ Board Meeting
The Food Standards Australia and New Zealand board met on 5th August 2026, with decisions published on 17 August.
Of particular relevance to biotechnology and fermentation-derived food ingredients, the Board approved:
A1338 – triacylglycerol lipase produced using Komagataella phaffii containing a gene from Yarrowia lipolytica, for use as a processing aid; and
A1345 – dextransucrase produced using Bacillus subtilis containing a gene from Streptococcus salivarius, also as a processing aid.
The Board additionally approved chitosan extracted from white button mushrooms (Agaricus bisporus) as a processing aid. The decisions were notified to the Food Ministers' Meeting, which has 60 days to request review before Code variations can take legal effect. Read more here.
Singapore
The Singapore Food Agency has updated their list of approved novel foods to include Aleph Farms´ Cultivated Thin-Cut Steak. This now includes six cultivated products out of the 18 approved novel foods: View the list here.
OECD
Guidance Document for In Vitro Testing of the Intestinal Fate of Orally Ingested Nanomaterials
New guidance provides recommendations for in vitro testing of the intestinal fate of orally ingested nanomaterials, supporting their safety assessment within regulatory frameworks. It covers simulated digestion methods, intestinal barrier models, nanomaterial uptake and translocation, and approaches for data interpretation and reporting. Read the guidance here.
Guidance Document on Toxicokinetics to accommodate Testing of (Nano)particles
New guidance covers in vivo toxicokinetic testing of manufactured (nano)particles following oral and inhalation exposure. It provides recommendations on study design, analytical methods and reporting, with a focus on factors such as dissolution, particle size, agglomeration and biotransformation. Read the guidance here.
Have any questions about how these developments could affect your products or regulatory strategy? Get in touch with the Atova team – we’re here to help you navigate the evolving regulatory landscape with confidence.
Contact us at: info@atovaconsulting.com
Subscribe to keep up-to-date with all the major regulatory updates & news:






Comments